Ticker League

Total Equity for AstraZeneca (AZN) 1990-2026

As of · Reported

Metric

Latest period

$47.3B

YoY change

+19.3%

5Y CAGR

+25.5%

Peak year (FY2025)

$48.7B

Total Equity history chart for AstraZeneca (AZN) from 2016 to 2025

Latest: $48.7B

Total Equity growth chart for AstraZeneca (AZN) from 2016 to 2025

Latest: +19.3%

Total Equity history table for AstraZeneca (AZN) from 1990 to 2025

  • FY2025$48.7B+19.3%
  • FY2024$40.8B+4.2%
  • FY2023$39.1B+5.7%
  • FY2022$37B-5.7%
  • FY2021$39.3B+151.4%
  • FY2020$15.6B+19.0%
  • FY2019$13.1B+5.3%
  • FY2018$12.5B-16.7%
  • FY2017$15B+0.7%
  • FY2016$14.9B-19.7%
  • FY2015$18.5B-5.8%
  • FY2014$19.6B-15.5%
  • FY2013$23.2B-2.2%
  • FY2012$23.7B+2.1%
  • FY2011$23.2B+0.1%
  • FY2010$23.2B+12.4%
  • FY2009$20.7B+29.8%
  • FY2008$15.9B+7.7%
  • FY2007$14.8B-3.4%
  • FY2006$15.3B+12.6%
  • FY2005$13.6B-5.6%
  • FY2004$14.4B+9.3%
  • FY2003$13.2B+18.0%
  • FY2002$11.2B-18.5%
  • FY2001$13.7B+43.9%
  • FY2000$9.53B-7.5%
  • FY1999$10.3B+146.8%
  • FY1998$4.17B+16.9%
  • FY1997$3.57B+2.5%
  • FY1996$3.48B+21.1%
  • FY1995$2.88B+9.2%
  • FY1994$2.63B+18.8%
  • FY1993$2.22B+2558.1%
  • FY1992$83.4M-89.3%
  • FY1991$782M+37.0%
  • FY1990$571M—

Total Equity values are taken from AstraZeneca's reported balance sheets (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Total Equity at AstraZeneca (AZN)

According to AstraZeneca's latest reported financial statements, the company's latest reported total equity is $47.3B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

AstraZeneca (AZN) most recent annual total equity stands at $48.7B (2025) – grew 19.3% year-over-year.

AstraZeneca total equity compound annual growth for the 2020–2025 (5 years) window is +25.5%, sustaining 3 straight years of year-over-year growth.

The record annual total equity stands at $48.7B, reached in 2025; the historical low of $83.4M was recorded in 1992.

AstraZeneca Total Equity by Year

AstraZeneca Total Equity 2025: $48.7B

AstraZeneca total equity in 2025 was $48.7B, grew 19.3% from 2024. This figure represents the highest annual value in the available history.

AstraZeneca Total Equity 2024: $40.8B

2024's total equity for AstraZeneca came in at $40.8B, edged up 4.2% from 2023.

AstraZeneca Total Equity 2023: $39.1B

AstraZeneca posted total equity of $39.1B in 2023, grew 5.7% from 2022.

AstraZeneca Total Equity 2022: $37B

In 2022, AstraZeneca reported total equity of $37B, declined 5.7% below 2021.

AstraZeneca Total Equity 2021: $39.3B

AstraZeneca total equity in 2021 was $39.3B.

See more financial history for AstraZeneca (AZN).

Sector peers by Total Equity

Healthcare peers of AstraZeneca (AZN), ranked by their latest total equity

Frequently asked questions

AstraZeneca (AZN) Key Financials

Charts, filings, and peer comparison for every metric

Operations

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview
Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.